ECTRIMS eLearning

Inflammatory active peri- and postmenopausal patients in multiple sclerosis – a crosssectional study
ECTRIMS Learn. Elias-Hamp B. 10/25/17; 199379; EP1358
Birte Elias-Hamp
Birte Elias-Hamp
Contributions
Abstract

Abstract: EP1358

Type: ePoster

Abstract Category: Clinical aspects of MS - 6 MS and gender

Objective: The objective was to determine MS disease activity peri- and postmenopausal in comparison to not menopausal patients in our private practice in Hamburg, Germany. Disease activity was documented via MRI and relapse rate.
Background: MS is widely known as a common neurological disease in especially young female patients. But these patients get older, and data on disease activity in peri- and postmenopausal MS patients are scarce. According to lacking experience neurologists may expect, that after or around menopause MS disease activity may disappear and therefore stop disease modifying therapy.
Design and methods: In our private practice 410 women with MS were retrospectively enrolled into the study. Detailed information on the course of MS (relapses before 10, 5 and 2 years) as well as MRI-data in the most recent MRI (active T1-lesions, progress of T2-lesions) was obtained with a questionnaire developed for gynecologic and neurologic purposes.
Results: 304 questionnaires were included into analysis. 190 patients (62,5%) were not menopausal, 83 patients (27%) peri- and 24 patients (8%) postmenopausal, 7 patients (2%) remain unknown.
As to expect relapse activity was higher in not menopausal patients (57%), but still 38% of the perimenopausal patients had relapses in the last 2 years.
Whereas 11,4% of the not menopausal patients had active T1-lesions, 7,1% of the perimenopausal patients showed activity in the MRI.
Progress in T2-lesions was higher in not menopausal patients (30,3%) compared to peri- and postmenopausal patients (14,1%).
Conclusions: Disease activity in MS seems to decline with older age and during hormonal changes (menopause) in female patients, but in some of the patients disease activity is persisting clinically and in neuroimaging even in a higher age.
Clinical and radiological disease activity should therefore continuously be monitored and disease modifying therapy adjusted accordingly.
Disclosure: Study supported by Genzyme.
Birte Elias-Hamp: Has received speaker honoraria, payments for consultancy and research grants from Biogen, Merck Serono, Bayer Healthcare, Almirall, Novartis, Teva, Genzyme, Roche and received travel expense compensation from Bayer Healthcare, Biogen, Genzyme, Merck Serono, Novartis and Teva.
Cornelia Hebell-Siewers: Has received speaker honoraria, payments for consultancy and travel expense compensation from Teva, Merck Serono, Otsuka, Janssen, Bayer Healthcare, Biogen and Genzyme.
Kerstin Hellwig: Has received speaker honoraria, payments for consultancy, research grants and travel expense compensation from Biogen, Merck Serono, Bayer Healthcare, Almirall, Novartis, Teva, Genzyme and Roche.
Lena Feddersen: Has nothing to disclose.
Wolfgang-G. Elias: Has received speaker honoraria, payments for consultancy and travel expense compensation from Biogen, Merck Serono, Bayer Healthcare, Almirall, Novartis, Teva and Genzyme.

Abstract: EP1358

Type: ePoster

Abstract Category: Clinical aspects of MS - 6 MS and gender

Objective: The objective was to determine MS disease activity peri- and postmenopausal in comparison to not menopausal patients in our private practice in Hamburg, Germany. Disease activity was documented via MRI and relapse rate.
Background: MS is widely known as a common neurological disease in especially young female patients. But these patients get older, and data on disease activity in peri- and postmenopausal MS patients are scarce. According to lacking experience neurologists may expect, that after or around menopause MS disease activity may disappear and therefore stop disease modifying therapy.
Design and methods: In our private practice 410 women with MS were retrospectively enrolled into the study. Detailed information on the course of MS (relapses before 10, 5 and 2 years) as well as MRI-data in the most recent MRI (active T1-lesions, progress of T2-lesions) was obtained with a questionnaire developed for gynecologic and neurologic purposes.
Results: 304 questionnaires were included into analysis. 190 patients (62,5%) were not menopausal, 83 patients (27%) peri- and 24 patients (8%) postmenopausal, 7 patients (2%) remain unknown.
As to expect relapse activity was higher in not menopausal patients (57%), but still 38% of the perimenopausal patients had relapses in the last 2 years.
Whereas 11,4% of the not menopausal patients had active T1-lesions, 7,1% of the perimenopausal patients showed activity in the MRI.
Progress in T2-lesions was higher in not menopausal patients (30,3%) compared to peri- and postmenopausal patients (14,1%).
Conclusions: Disease activity in MS seems to decline with older age and during hormonal changes (menopause) in female patients, but in some of the patients disease activity is persisting clinically and in neuroimaging even in a higher age.
Clinical and radiological disease activity should therefore continuously be monitored and disease modifying therapy adjusted accordingly.
Disclosure: Study supported by Genzyme.
Birte Elias-Hamp: Has received speaker honoraria, payments for consultancy and research grants from Biogen, Merck Serono, Bayer Healthcare, Almirall, Novartis, Teva, Genzyme, Roche and received travel expense compensation from Bayer Healthcare, Biogen, Genzyme, Merck Serono, Novartis and Teva.
Cornelia Hebell-Siewers: Has received speaker honoraria, payments for consultancy and travel expense compensation from Teva, Merck Serono, Otsuka, Janssen, Bayer Healthcare, Biogen and Genzyme.
Kerstin Hellwig: Has received speaker honoraria, payments for consultancy, research grants and travel expense compensation from Biogen, Merck Serono, Bayer Healthcare, Almirall, Novartis, Teva, Genzyme and Roche.
Lena Feddersen: Has nothing to disclose.
Wolfgang-G. Elias: Has received speaker honoraria, payments for consultancy and travel expense compensation from Biogen, Merck Serono, Bayer Healthcare, Almirall, Novartis, Teva and Genzyme.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies